Latest Articles
- Research ArticleIgG4 Valency Modulates the Pathogenicity of Anti–Neurofascin-155 IgG4 in Autoimmune NodopathyAlexandre Jentzer, Arthur Attal, Clémence Roué, et al.August 10, 2022
- RESEARCH ARTICLECerebellar Ataxia With Anti-DNER AntibodiesOutcomes and Immunologic FeaturesElise Peter, Le Duy Do, Salem Hannoun, et al.August 08, 2022
- Research ArticleRituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum DisordersA 14-Year Real-Life ExperienceSu-Hyun Kim, Na Young Park, Ki Hoon Kim, et al.July 19, 2022
- Research ArticleIncreased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple SclerosisRikke Holm Hansen, Jacob Talbot, Helene Højsgaard Chow, et al.July 14, 2022
- Research ArticleImmune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar DegenerationElise Peter, Isabelle Treilleux, Valentin Wucher, et al.July 12, 2022
- Research ArticleLong-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person SyndromeJessica Yi, Marinos C. DalakasJuly 07, 2022
- Research ArticleParaneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo AutoantibodiesMichael Winklehner, Jan Bauer, Verena Endmayr, et al.July 07, 2022
- Clinical/Scientific NoteThe BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG AntibodiesChiara Briani, Andrea Visentin, Francesca Castellani, et al.July 07, 2022
Pages
Advertisement